Correlation of Dopaminergic Denervation and the Progression of Autonomic Dysfunctions in Different Clinical Subtypes of Parkinson’s Disease

Table 3

Aggravation of MDS-UPDRS scores, SCOPA-AUT, and putaminal SBRs during the follow-up of each subtype.

	TD subtype (n = 221)	Indeterminate subtype (n = 29)	PIGD subtype (n = 75)	value
MDS-UPDRS Part I score 12 months	2.5 ± 1.9	2.7 ± 2.3	2.8 ± 1.9	0.39
MDS-UPDRS Part I score 24 months	2.7 ± 2.0	2.9 ± 2.1	3.2 ± 2.7	0.50
MDS-UPDRS Part I score 48 months	3.0 ± 2.4^a	4.0 ± 2.8^b	3.8 ± 3.5	<0.05
MDS-UPDRS Part II score 12 months	7.5 ± 4.6^a	11.0 ± 4.8^b	9.0 ± 4.6	<0.01
MDS-UPDRS Part II score 24 months	8.1 ± 4.7^a	11.9 ± 5.3^b	9.4 ± 5.6	<0.01
MDS-UPDRS Part II score 48 months	10.3 ± 6.0^a	13.9 ± 6.2^b	11.5 ± 7.8	<0.05
MDS-UPDRS Part III score 12 months	22.8 ± 10.1	27.8 ± 9.3	23.0 ± 10.7	0.06
MDS-UPDRS Part III score 24 months	24.3 ± 11.2^a	30.0 ± 11.8^b	26.6 ± 12.0	<0.05
MDS-UPDRS Part III score 48 months	29.8 ± 11.2	32.5 ± 12.4	30.9 ± 14.2	0.57
SCOPA-AUT 12 months	9.3 ± 7.0^a	12.6 ± 7.6^b	11.0 ± 6.7^b	<0.05
SCOPA-AUT 24 months	12.1 ± 7.0	14.1 ± 6.1	13.1 ± 7.9	0.21
SCOPA-AUT 48 months	12.3 ± 7.3^a	16.0 ± 7.4^b	13.4 ± 8.5^a	<0.05
12-month caudate SBR	1.7 ± 0.5^a	1.4 ± 0.4^b	1.5 ± 0.5^b	<0.01
24-month caudate SBR	1.6 ± 0.5^a	1.3 ± 0.4^b	1.4 ± 0.5^b	<0.01
48-month caudate SBR	1.4 ± 0.5	1.1 ± 0.4	1.2 ± 0.5	0.05
12-month putaminal SBR	0.6 ± 0.2^a	0.5 ± 0.2	0.5 ± 0.2^b	<0.05
24-month putaminal SBR	0.6 ± 0.2^a	0.5 ± 0.2^b	0.5 ± 0.2	<0.05
48-month putaminal SBR	0.5 ± 0.2	0.4 ± 0.2	0.4 ± 0.2	0.06

For a particular variable, values with different superscripts indicate a statistically significant difference. MDS-UPDRS: Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; SCOPA-AUT: Scale for Outcomes in Parkinson’s Disease-Autonomic; SBR: specific binding ratio.